Welcome to our dedicated page for IonQ SEC filings (Ticker: IONQ-WT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on IonQ's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into IonQ's regulatory disclosures and financial reporting.
IonQ, Inc. has filed a prospectus supplement for the potential resale, from time to time, by selling stockholders of up to 1,958,951 shares of its common stock. This is a resale registration; the company states it will not receive any proceeds from sales under this supplement.
The shares represent a small portion of IonQ’s equity base, with 381,002,314 shares outstanding as of July 29, 2026, and the number of outstanding shares will not change as a result of these resales. IonQ describes itself as a quantum platform company offering quantum computing, networking, sensing and security solutions, including cloud access through major hyperscalers and its own service, as well as satellite-based quantum-secure communications.
The company reports that it remains in early commercial stages and has incurred substantial losses, with net losses attributable to IonQ of $510.4 million, $331.6 million and $157.8 million for 2025, 2024 and 2023, respectively, and an accumulated deficit of $1,194.1 million as of December 31, 2025. The filing highlights risks that future sales by selling stockholders, and by directors and officers who are not subject to lock-up agreements, could put pressure on the market price of the common stock.